

Data Sharing Statement

Cortés. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer. *JAMA Oncol*. Published June 25, 2020. 10.1001/jamaoncol.2020.1796

Data

Data available: Yes

Data types: Deidentified participant data

How to access data: www.clinicalstudydatarequest.com

When available: beginning date: 04-13-2018

Supporting Documents

Document types: None

Additional Information

Who can access the data: N/A

Types of analyses: N/A

Mechanisms of data availability: N/A

Any additional restrictions: Qualified researchers may request access to deidentified patient level data through the Clinical Study Data Request platform (<https://www.clinicalstudydatarequest.com/>) and will be provided with accompanying clinical study documentation (protocol and any associated amendments, annotated case report form, reporting and analysis plan, dataset specifications, and the clinical study report). Researchers requesting access to clinical study documentation only can do so via the following link:

https://www.roche.com/research_and_development/who_we_are/how_we_work/clinical_trials/our_commitment_to_data_sharing/clinical_study_documents_request_form.htm. Documents are made available on application, per scope and timing criteria as published on the Clinical Study Data Request platform.